Motley fool talking like a usual speculator. They could raise cash at a high SP but may not need to as it'll dilute future earnings per share etc. They also have the new product "oscar2" with sphygmocor inside chasing ce mark and FDA approval this year. The margins on the shpygmocor pulls around 85% and the coys well run with bugger all expenses. I reckon we should be at 80c + come the end.of the yr.
The next nanosonics or impedimed, page-4
-
- There are more pages in this discussion • 35 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
